Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry

Hadi Yaziji, Clive R. Taylor, Neal S. Goldstein, David J. Dabbs, Elizabeth H. Hammond, Bryan Hewlett, Alton D. Floyd, Todd S. Barry, Alvn W. Martin, Sunil Badve, Frederick Baehner, Richard W. Cartun, Richard N. Eisen, Paul E. Swanson, Stephen M. Hewitt, Mogen Vyberg, David G. Hicks

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing-preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.

Original languageEnglish
Pages (from-to)513-520
Number of pages8
JournalApplied Immunohistochemistry and Molecular Morphology
Volume16
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Estrogen Receptors
Immunohistochemistry
Breast Neoplasms
Biomarkers
Guidelines
Therapeutics

Keywords

  • Breast cancer
  • ER
  • Estrogen receptor
  • IHC
  • Immunohistochemistry
  • Standardization

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology
  • Medicine(all)

Cite this

Yaziji, H., Taylor, C. R., Goldstein, N. S., Dabbs, D. J., Hammond, E. H., Hewlett, B., ... Hicks, D. G. (2008). Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 16(6), 513-520. https://doi.org/10.1097/PAI.0b013e31818a9d3a

Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. / Yaziji, Hadi; Taylor, Clive R.; Goldstein, Neal S.; Dabbs, David J.; Hammond, Elizabeth H.; Hewlett, Bryan; Floyd, Alton D.; Barry, Todd S.; Martin, Alvn W.; Badve, Sunil; Baehner, Frederick; Cartun, Richard W.; Eisen, Richard N.; Swanson, Paul E.; Hewitt, Stephen M.; Vyberg, Mogen; Hicks, David G.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 16, No. 6, 12.2008, p. 513-520.

Research output: Contribution to journalArticle

Yaziji, H, Taylor, CR, Goldstein, NS, Dabbs, DJ, Hammond, EH, Hewlett, B, Floyd, AD, Barry, TS, Martin, AW, Badve, S, Baehner, F, Cartun, RW, Eisen, RN, Swanson, PE, Hewitt, SM, Vyberg, M & Hicks, DG 2008, 'Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry', Applied Immunohistochemistry and Molecular Morphology, vol. 16, no. 6, pp. 513-520. https://doi.org/10.1097/PAI.0b013e31818a9d3a
Yaziji, Hadi ; Taylor, Clive R. ; Goldstein, Neal S. ; Dabbs, David J. ; Hammond, Elizabeth H. ; Hewlett, Bryan ; Floyd, Alton D. ; Barry, Todd S. ; Martin, Alvn W. ; Badve, Sunil ; Baehner, Frederick ; Cartun, Richard W. ; Eisen, Richard N. ; Swanson, Paul E. ; Hewitt, Stephen M. ; Vyberg, Mogen ; Hicks, David G. / Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. In: Applied Immunohistochemistry and Molecular Morphology. 2008 ; Vol. 16, No. 6. pp. 513-520.
@article{764b7f54b8a8407e82680438b05069e5,
title = "Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry",
abstract = "Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of {"}false-negative{"} results worldwide. Standardized testing is only possible after all aspects of ER testing-preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the {"}ad-hoc committee{"} of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.",
keywords = "Breast cancer, ER, Estrogen receptor, IHC, Immunohistochemistry, Standardization",
author = "Hadi Yaziji and Taylor, {Clive R.} and Goldstein, {Neal S.} and Dabbs, {David J.} and Hammond, {Elizabeth H.} and Bryan Hewlett and Floyd, {Alton D.} and Barry, {Todd S.} and Martin, {Alvn W.} and Sunil Badve and Frederick Baehner and Cartun, {Richard W.} and Eisen, {Richard N.} and Swanson, {Paul E.} and Hewitt, {Stephen M.} and Mogen Vyberg and Hicks, {David G.}",
year = "2008",
month = "12",
doi = "10.1097/PAI.0b013e31818a9d3a",
language = "English",
volume = "16",
pages = "513--520",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry

AU - Yaziji, Hadi

AU - Taylor, Clive R.

AU - Goldstein, Neal S.

AU - Dabbs, David J.

AU - Hammond, Elizabeth H.

AU - Hewlett, Bryan

AU - Floyd, Alton D.

AU - Barry, Todd S.

AU - Martin, Alvn W.

AU - Badve, Sunil

AU - Baehner, Frederick

AU - Cartun, Richard W.

AU - Eisen, Richard N.

AU - Swanson, Paul E.

AU - Hewitt, Stephen M.

AU - Vyberg, Mogen

AU - Hicks, David G.

PY - 2008/12

Y1 - 2008/12

N2 - Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing-preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.

AB - Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing-preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.

KW - Breast cancer

KW - ER

KW - Estrogen receptor

KW - IHC

KW - Immunohistochemistry

KW - Standardization

UR - http://www.scopus.com/inward/record.url?scp=67650284116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650284116&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e31818a9d3a

DO - 10.1097/PAI.0b013e31818a9d3a

M3 - Article

VL - 16

SP - 513

EP - 520

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 6

ER -